Nurix Therapeutics(US:NRIX) Globenewswire·2025-05-14 13:30Core Insights - Nurix Therapeutics, Inc. is advancing its clinical-stage biopharmaceutical efforts with the presentation of data from its ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia at major scientific conferences [1][2] Group 1: Clinical Trial Presentations - Data from the Phase 1a/b clinical trial will be presented at the European Hematology Association 2025 Congress in Milan, Italy, from June 12–15, 2025, and at the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland, from June 17–21, 2025 [2] - The EHA 2025 presentation will include findings on the rapid and durable clinical responses of bexobrutideg in relapsed refractory CLL, with Dr. Zulfa Omer as the presenting author [3] - An oral presentation at the 18-ICML will also cover updated findings from the Phase 1a study of bexobrutideg in relapsed refractory CLL, presented by Dr. Alexey Danilov [4] Group 2: Drug Profile - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule that acts as a degrader of Bruton's tyrosine kinase (BTK), currently evaluated in a Phase 1 clinical trial for relapsed or refractory B cell malignancies [6] - The drug is designed to penetrate the brain and is part of a broader strategy by Nurix to develop targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [7][8] Group 3: Company Overview - Nurix Therapeutics focuses on the discovery, development, and commercialization of targeted protein degradation medicines, positioning itself at the forefront of innovative drug design [7] - The company has a pipeline that includes BTK degraders and CBL-B inhibitors, with collaborations with major pharmaceutical companies like Gilead Sciences, Sanofi, and Pfizer [8]